Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
S100A9: A New Target for the Development of Drugs Addressing Chronic Inflammation
AmorChem Canada flag Canada
Abstract ID:
The anti-S100A9 monoclonal antibody is directed against a novel target covering chronic inflammation and autoimmune diseases....
Contact John Clement
Participants
You
Email me a copy of this message

The technology is based on a novel target, the S100A9 protein which plays a critical role in turning acute inflammation into a chronic state. The S100A9 protein acts as an amplifier of leukocyte migration during inflammation. It is also a potent inducer of pro-inflammatory cytokine production like TNFα, IL-1β, and IL-6. As such, S100A9 represents a very promising new therapeutic target for the control of inflammation. Anti-S100A9 antibodies have been developed and have been shown to be as efficacious as anti-TNF in mouse models of Crohn's disease and rheumatoid arthritis.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION